List view / Grid view
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
The designers of the Dual Chimeric Antigen Receptor (CAR) T cell therapy report it slows HIV replication and leads to a smaller viral reservoir in HIV-infected mice.
Researchers have shown that a mutation in the n-Tr20 gene can alter brain function and behaviour, while loss of the gene made mice resistant to seizures.
The developers of a temporary coating which adheres to the small intestine demonstrated it could be modified to deliver drugs, aid digestion and stop absorption of glucose.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
Researchers have discovered compounds able to restart production of VEGF-A in cellular models, which rebuilds blood vessels and muscle in damaged heart tissue.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
Multiplexing allows multiple biological target analytes to be simultaneously examined and quantified in a single sample. It’s a technique widely used by scientific researchers of all disciplines and provides many benefits.
Researchers reveal their antibiotics disrupt the bacterial TonB system which uropathogenic E. coli (UPEC) uses to uptake iron in order to cause urinary tract infections.
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
